ResultsIQ

ResultsIQ › Latest results › Cipla Limited

Cipla Limited Q4 FY26 results deck summary

NSE: CIPLA · BSE: 500087

Results deck of 13 May 2026, summarised by AI from the filing.

4 respiratory assets expected commercialization in FY27; gVentolin launch expected in coming months.

Key takeaways

  1. Guidance 4 respiratory assets expected commercialization in FY27; gVentolin launch expected in coming months.
  2. Change Q4FY26 EBITDA margin 15.2% vs 22.8% in Q4FY25.
  3. Risk North America faces near-term challenges.

Original filing on BSE

Cipla Limited Q1 FY27 results

As filed: Revenue ₹7,119 cr (+2% year on year), EBITDA ₹1,192 cr (−33% year on year), PAT ₹786 cr (−39% year on year), EBITDA margin 16.8% (−881 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹6,541 cr (−3% year on year), EBITDA ₹955 cr (−38% year on year), PAT ₹543 cr (−55% year on year), EBITDA margin 14.6% (−825 bps). Score 13 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 825 bps year on year. Revenue fell 8% from last quarter. Share price after the results: +7.5% in 30 days (Nifty 500: +1.3%).
  • Q3 FY26: Revenue ₹7,074 cr (0% year on year), EBITDA ₹1,255 cr (−37% year on year), PAT ₹674 cr (−39% year on year), EBITDA margin 17.7% (−1,000 bps). Score 7 of 100, Below trend. Revenue, EBITDA and profit before exceptional items growth were well below the company's own trend. EBITDA margin fell 1000 bps year on year. Revenue fell 7% from last quarter. Share price after the results: −2.1% in 28 days (Nifty 500: +1.7%).
  • Q2 FY26: Revenue ₹7,589 cr (+8% year on year), EBITDA ₹1,895 cr (+1% year on year), PAT ₹1,353 cr (+4% year on year), EBITDA margin 25.0% (−176 bps). Score 27 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 176 bps year on year. Share price after the results: −3.1% in 29 days (Nifty 500: −0.1%).
  • Q1 FY26: Revenue ₹6,957 cr (+4% year on year), EBITDA ₹1,778 cr (+4% year on year), PAT ₹1,292 cr (+10% year on year), EBITDA margin 25.6% (−8 bps). Score 26 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA and profit growth were well below it. EBITDA margin was flat year on year. Profit rose ₹117 cr on a year ago, against ₹177 cr the year before. Share price after the results: +7.1% in 28 days (Nifty 500: −1.3%).
  • Q4 FY25: Revenue ₹6,730 cr (+9% year on year), EBITDA ₹1,538 cr (+17% year on year), PAT ₹1,214 cr (+30% year on year), EBITDA margin 22.9% (+150 bps). Score 57 of 100, In line with trend. Revenue and profit growth were in line with the company's own trend; EBITDA growth was above it. EBITDA margin rose 150 bps year on year. Revenue fell 5% from last quarter. Share price after the results: −0.6% in 30 days (Nifty 500: +2.4%).
  • Q3 FY25: Revenue ₹7,073 cr (+7% year on year), EBITDA ₹1,989 cr (+14% year on year), PAT ₹1,575 cr (+47% year on year), EBITDA margin 28.1% (+167 bps). Score 57 of 100, In line with trend. Revenue and EBITDA growth were in line with the company's own trend; profit growth was above it. EBITDA margin rose 167 bps year on year. Profit rose ₹507 cr on a year ago, more than the ₹260 cr it added the year before.
  • Q2 FY25: Revenue ₹7,051 cr (+6% year on year), EBITDA ₹1,885 cr (+9% year on year), PAT ₹1,305 cr (+13% year on year), EBITDA margin 26.7% (+77 bps). Score 47 of 100, In line with trend. EBITDA margin rose 77 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Cipla Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.